Skip to main content
Top
Published in: Digestive Diseases and Sciences 7/2009

01-07-2009 | Stanford Multidisciplinary Seminars

Successful Use of Octreotide to Treat Ménétrier’s Disease: A Rare Cause of Abdominal Pain, Weight Loss, Edema, and Hypoalbuminemia

Authors: Michael Rothenberg, Reetesh Pai, Kevin Stuart

Published in: Digestive Diseases and Sciences | Issue 7/2009

Login to get access

Excerpt

A 75-year-old man presented with steadily increasing upper abdominal pain, worse after meals, over 6 weeks. He also described anorexia, early satiety, intermittent post-prandial nausea and bilious vomiting, as well as bilateral ankle edema and an unintentional 10-lb weight loss, despite daily use of lansoprazole and furosemide. He described no heartburn, dysphagia, melena, hematemesis, diarrhea, fevers, night sweats, or other cardiopulmonary or urinary symptoms. His past medical history was notable for mild gastroesophageal reflux, hypertension, depression, and benign prostatic hyperplasia. Current medications included lansoprazole, valsartan, furosemide, and escitalopram. He had a negative family history and did not smoke or drink alcohol. Physical examination was normal except for 2+ bilateral pitting edema to the knees. …
Literature
1.
go back to reference Gadour MO, Salman AH, El Samman el Tel W, et al. Ménétrier’s disease: an excellent response to octreotide. A case report from the Middle East. Trop Gastroenterol. 2005;26:129–131.PubMed Gadour MO, Salman AH, El Samman el Tel W, et al. Ménétrier’s disease: an excellent response to octreotide. A case report from the Middle East. Trop Gastroenterol. 2005;26:129–131.PubMed
3.
go back to reference Yeaton P, Frierson HF Jr. Octreotide reduces enteral protein losses in Ménétrier’s disease. Am J Gastroenterol. 1993;88:95–98.PubMed Yeaton P, Frierson HF Jr. Octreotide reduces enteral protein losses in Ménétrier’s disease. Am J Gastroenterol. 1993;88:95–98.PubMed
4.
go back to reference Coffey RJ, Washington MK, Corless CL, et al. Ménétrier disease and gastrointestinal stromal tumors: hyperproliferative disorders of the stomach. J Clin Invest. 2007;117:70–80. doi: 10.1172/JCI30491.PubMedCrossRef Coffey RJ, Washington MK, Corless CL, et al. Ménétrier disease and gastrointestinal stromal tumors: hyperproliferative disorders of the stomach. J Clin Invest. 2007;117:70–80. doi: 10.​1172/​JCI30491.PubMedCrossRef
5.
go back to reference Lee EL, Feldman M. Gastritis and gastropathies. In: Feldman M, Friedman LS, eds. Sleisenger & Fordtran’s Gastrointestinal and Liver Disease, 8th edn. Philadelphia: Saunders; 2006:1068–1088. Lee EL, Feldman M. Gastritis and gastropathies. In: Feldman M, Friedman LS, eds. Sleisenger & Fordtran’s Gastrointestinal and Liver Disease, 8th edn. Philadelphia: Saunders; 2006:1068–1088.
7.
go back to reference Dempsey PJ, Goldenring JR, Soroka CJ, et al. Possible role of transforming growth factor alpha in the pathogenesis of Ménétrier’s disease: supportive evidence form humans and transgenic mice. Gastroenterology. 1992;103:1950–1963.PubMed Dempsey PJ, Goldenring JR, Soroka CJ, et al. Possible role of transforming growth factor alpha in the pathogenesis of Ménétrier’s disease: supportive evidence form humans and transgenic mice. Gastroenterology. 1992;103:1950–1963.PubMed
8.
go back to reference Takagi H, Jhappan C, Sharp R, et al. Hypertrophic gastropathy resembling Ménétrier’s disease in transgenic mice overexpressing transforming growth factor alpha in the stomach. J Clin Invest. 1992;90:1161–1167. doi: 10.1172/JCI115936.PubMedCrossRef Takagi H, Jhappan C, Sharp R, et al. Hypertrophic gastropathy resembling Ménétrier’s disease in transgenic mice overexpressing transforming growth factor alpha in the stomach. J Clin Invest. 1992;90:1161–1167. doi: 10.​1172/​JCI115936.PubMedCrossRef
9.
go back to reference Pinski J, Halmos G, Schally AV. Somatostatin analog RC-160 and bombesin/gastrin-releasing peptide antagonist RC-3095 inhibit the growth of androgen-independent DU-145 human prostate cancer line in nude mice. Cancer Lett. 1993;71:189–196. doi: 10.1016/0304-3835(93)90115-P.PubMedCrossRef Pinski J, Halmos G, Schally AV. Somatostatin analog RC-160 and bombesin/gastrin-releasing peptide antagonist RC-3095 inhibit the growth of androgen-independent DU-145 human prostate cancer line in nude mice. Cancer Lett. 1993;71:189–196. doi: 10.​1016/​0304-3835(93)90115-P.PubMedCrossRef
11.
go back to reference Watt HL, Kharmate GD, Kumar U. Somatostatin receptors 1 and 5 heterodimerize with epidermal growth factor receptor: agonist-dependent modulation of the downstream MAPK signalling pathway in breast cancer cells. Cell Signal. 2009;21:428–439.PubMedCrossRef Watt HL, Kharmate GD, Kumar U. Somatostatin receptors 1 and 5 heterodimerize with epidermal growth factor receptor: agonist-dependent modulation of the downstream MAPK signalling pathway in breast cancer cells. Cell Signal. 2009;21:428–439.PubMedCrossRef
13.
Metadata
Title
Successful Use of Octreotide to Treat Ménétrier’s Disease: A Rare Cause of Abdominal Pain, Weight Loss, Edema, and Hypoalbuminemia
Authors
Michael Rothenberg
Reetesh Pai
Kevin Stuart
Publication date
01-07-2009
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 7/2009
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-009-0754-z

Other articles of this Issue 7/2009

Digestive Diseases and Sciences 7/2009 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.